Engineered extracellular vesicles encapsulated Bryostatin-1 as therapy for neuroinflammation.
Publication/Presentation Date
2-10-2022
Abstract
Targeted and effective drug delivery to central nervous system (CNS) lesions is a major challenge in the treatment of multiple sclerosis (MS). Extracellular vesicles (EVs) have great promise as a drug delivery nanosystem given their unique characteristics, including a strong cargo-loading capacity, low immunogenicity, high biocompatibility, inherent stability, high delivery efficiency, ease of manipulation, and blood-brain barrier (BBB) penetration. Clinical applications are, however, limited by their insufficient targeting capability and "dilution effects" upon systemic administration. Neural stem cells (NSCs) provide an abundant source of EVs because of their remarkable capacity for self-renewal. Here, we developed a novel therapeutic strategy for local delivery and treatment using EVPs, which are derived from NSCs with the expression of the CNS lesion targeting ligand-PDGFRα. Furthermore, we used EVPs as a targeting carrier for encapsulating Bryostatin-1 (Bryo-1), a natural compound with remarkable anti-inflammation ability. Our data showed that Bryo-1 delivered by EVPs was more stable and concentrated in the CNS than native Bryo-1. Systemic injection of a low dosage (1 × 10
Volume
14
Issue
6
First Page
2393
Last Page
2410
ISSN
2040-3372
Published In/Presented At
Wu, W. C., Tian, J., Xiao, D., Guo, Y. X., Xiao, Y., Wu, X. Y., Casella, G., Rasouli, J., Yan, Y. P., Rostami, A., Wang, L. B., Zhang, Y., & Li, X. (2022). Engineered extracellular vesicles encapsulated Bryostatin-1 as therapy for neuroinflammation. Nanoscale, 14(6), 2393–2410. https://doi.org/10.1039/d1nr05517h
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
35088795
Department(s)
Administration and Leadership
Document Type
Article